Barts Hospital London are currently running a Prostate Cancer clinical trial looking at how to stop low and intermediate prostate cancer from developing into high risk cancer. The PROVENT study is a clinical trial for men diagnosed with prostate cancer who are on active surveillance. It aims to test whether Aspirin and/or Vitamin D3 have the potential to stop low and intermediate risk prostate cancers from developing into high risk cancers. Homerton University Hospital, University College London Hospital, St Bartholomew’s Hospital and University Hospital Coventry are all currently recruiting participants to the study.
NICE Guideline on Prostate cancer: Diagnosis and Management (Nov 2016 accelerated update) The draft scope for this NICE guideline is now out for consultation. Tackle will be submitting a response on the draft scope; it is a valuable opportunity to ensure that the guideline considers issues important to Tackle members. The NICE consultation page contains the documents, background papers and instructions on how organizations can comment. The consultation on this draft scope closes at 5pm on 14 July 2017.
A BBC News item found today at http://www.bbc.co.uk/news/health-40302692 says:-
Scientists have developed a blood test that could pick out which men with advanced prostate cancer would benefit from a new drug treatment. The test detects cancer DNA in the blood, helping doctors check whether precision drugs are working. Cancer Research UK said the test could "greatly improve survival". But larger studies involving more men needed to take place to confirm if doctors could rely on the test, the charity said.
Graham Fulford, founder of the Graham Fulford Charitable Trust is well known to our group as someone who is bringing PSA Testing to men around the country. He says:
‘We are proud to be able to announce that we are one of three hundred charities elected by the The Masonic Foundation to receive a grant of up to £25,000 from the Masonic Charity Foundation Community Awards Tercentenary Fund."
"The top two awards of £15,000 and £25,000 will be awarded on the basis of a public vote to take place between 12th June and 31st July 2017."
"We would be delighted if you could vote for us at mcf.org.uk/vote "
Please spread the word for us !
Reported on the BBC website on 3rd June:- Click here to see original BBC article
One of the largest clinical trials for prostate cancer has given "powerful results", say UK researchers. A drug for treating prostate cancer that has spread was found to save lives when offered earlier, a study found. The trial looked at abiraterone as an additional treatment in patients with prostate cancer who were about to start long-term hormone therapy. Abiraterone improved survival, according to results published in the New England Journal of Medicine.
According to the Institute of Cancer Research, (click to see original article) adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves patient survival by 37%, according to the results of one of the largest-ever clinical trials for prostate cancer. The results were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, and published in the New England Journal of Medicine on Saturday 3 June 2017. The results from the Cancer Research UK-funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first-line treatment alongside hormone therapy.
An email forwarded by Darrell at PCSNW to all members (from Roger Wotton?) is as follows..... I hope you will be able to join us for this year's AGM and Conference on Tuesday 13 June at 10.30am at Winterbourne House, Edgbaston, Birmingham which some of you will remember is where we held our 2015 AGM. To find out about registration and see all the papers required for the AGM including the agenda, click here. This event is generously sponsored by Prostate Cancer UK and so we would encourage as many support groups as possible to attend.
An email forwarded by Darrell at PCSNW to all members (from Roger Wotton?) is as follows..... Following our successful collaboration with Bayer Pharmaceutical last year which resulted in the “Manversation” guides being produced to encourage conversations around prostate cancer, I made the suggestion at the time that partners and wives play a very important role in supporting men who have been diagnosed. Building on this, Bayer (with support from PR Agency Cohn & Wolfe) are currently working on a proposal to deliver ‘A Woman’s guide to prostate cancer’.
The May issue is available on line at www.tackleprostate.org/newsletter-signup.php
Hard copies are being posted soon to those who have requested them .
Tackle Prostate Cancer is one of 19 cancer charities working together to campaign and lobby for better treatment and access to drugs. As a coalition, we are trying to have NHS England and NICE reconsider their plan to cap drug treatment costs. One of the actions we have taken is to try and get as many people as possible to sign a petition to stop this proposal. The petition has been developed by Prostate Cancer UK on behalf of all our charities. We urgently need your help, to persuade NHS England and the National Institute for Health and Care Excellence (NICE) to reconsider plans that threaten to have a devastating impact on men fighting prostate cancer in the future.